MRK Merck & Co
- 131.370
- +0.170+0.13%
Merck & Co News
Merck Announces Data For V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed For Adults
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious DiseasesResults build on the data supporting the clinical profile of
Major Bank Ratings | Damo: Raising Merck's Target Price to $132, Keytruda Continues Strong Growth
Glonghui, April 29 | Morgan Stanley published a research report stating that with the support of the anti-cancer drug Keytruda, Merck achieved another excellent first quarter results despite adverse factors from foreign exchange. The bank raised its 2024 earnings forecast for the company and raised its target price from $128 to $132. It believes that the focus for the rest of the year will be on the Winrevair listing. The initial comments are encouraging. The bank gave Merck a “in sync with the market” rating. According to the report, the new revenue guide is 63.1 billion yuan to 64.3 billion US dollars, while the bank raised its forecast from 64.5 billion yuan to 65 billion US dollars. The market forecast
Major Bank Ratings | Goldman Sachs: Raising Merck's Target Price to $144, Rating “Buy”
Glonghui, April 29 | Goldman Sachs released a report stating that Merck's performance is strong. In particular, the anti-cancer drug Keytruda grew 20% year over year, which is about 4% higher than the bank and market expectations. The overall execution capacity in the vaccine business is also excellent, and the company's stock price is relatively outperforming the market. The market is watching the news that the new drug Winrevair is on the market. The bank believes that Merck's pharmaceutical channel opportunities continue to increase, especially at the upcoming American Society of Clinical Oncology (ASCO) annual meeting. Although it is not expected that the company will disclose significant data, it can better understand its strategic initiatives. The bank will set Merck's price target from 139 US dollars
Merck Is Maintained at Buy by Truist Securities
Merck Is Maintained at Buy by Truist Securities
Truist Securities Maintains Buy on Merck & Co, Raises Price Target to $143
Truist Securities analyst Robyn Karnauskas maintains Merck & Co with a Buy and raises the price target from $142 to $143.
Merck & Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/26/2024 8.83% Truist Securities $142 → $143 Maintains Buy 04/18/2024 2.74% Cantor Fitzgerald → $135 Rei
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Jefferies Adjusts Merck & Company Price Target to $150 From $145
Merck & Company (MRK) has an average rating of outperform and price targets ranging from $114 to $155, according to analysts polled by Capital IQ. Price: 131.18, Change: +0.46, Percent Change: +0.35
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
The CNN Money Fear and Greed index showed a slight improvement in the overall market sentiment, while the index remained in the "Fear" zone on Thursday.U.S. stocks settled lower on Thursday, following
Express News | Damo: Raise Merck's target price to $132 and raise the 2024 profit forecast
Earnings Call Summary | Merck & Co(MRK.US) Q1 2024 Earnings Conference
The following is a summary of the Merck & Co., Inc. (MRK) Q1 2024 Earnings Call Transcript:Financial Performance:Total company revenues for Q1 2024 were $15.8 billion, up 9% or 12% excluding foreign e
US stocks closed | The three major indices collectively closed down. Nvidia reversed the market and rose nearly 4%, and Google rose more than 16% after the market
The S&P Index stopped three times in a row, the Dow fell two times in a row, Tesla rose 5%, fell 10% after Meta earnings report, the biggest decline in two years, Microsoft turned up and rose more than 5% after the market, and Intel fell 9% after the market.
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Wall Street suffers a double blow in Thursday's session, as softer-than-expected revenue forecasts from Meta Platforms Inc. (NASDAQ:META) are being compounded by weaker-than-expected economic growth a
Cantor Fitzgerald Adjusts Merck & Co.' Price Target to $155 From $135, Keeps Overweight Rating
Merck & Co. (MRK) has an average rating of outperform and price targets ranging from $114 to $148, according to analysts polled by Capital IQ. Price: 130.00, Change: +3.00, Percent Change: +2.36
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump
All three major Wall Street indexes were down in late-morning trading as investors processed a GDP report that showed slower-than-anticipated growth with persistently high inflation and earnings miss
S&P 500 Down Over 1%; Merck Increases 2024 Outlook
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling by around 250 points on Thursday.The Dow traded down 1.55% to 37,864.79 while the NASDAQ fell 1.60% to 15,460.95. The
Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended March 2024, Merck (MRK) reported revenue of $15.78 billion, up 8.9% over the same period last year. EPS came in at $2.07, compared to $1.40 in the year-ago quarter.
Research Alert: CFRA Retains Buy View On Shares Of Merck & Co., Inc
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our target to $146 from $137, 1
Changes in US stocks | MSD rose nearly 4%, Q1 net profit increased 69% year on year, raised full-year guidance
Glonghui on April 25 | MSD (MRK.US) rose 3.93% to $131.99. MSD's total global sales for the first quarter were US$15.8 billion, up 9% year on year; net profit was US$4.762 billion, up 69% year on year. The company expects full-year sales of $63.1 billion to $64.3 billion, compared to the previous forecast of $62.7 billion to $64.2 billion; the non-GAAP earnings per share range is $8.53 to $8.65, higher than the previous forecast of $8.44 to $8.59.
Rutgers Dual Degree Program Enabled Graduate Student to Pursue Interest in Healthcare While She Earned an MBA
The option of pursuing a Master's in Public Health and a Rutgers MBA was the "perfect fit."NEWARK, N.J., April 25, 2024 /PRNewswire/ -- After graduating from Cornell University, Daphni Sawyer worked
Analysis
Price Target
No Data
